Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279300 · ClinicalTrials.gov registry record · Phase 1
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1 study of Advanced Solid Tumor and Advanced Lymphoma, sponsored by CStone Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT05279300: Recruiting Phase 1 study of Advanced Solid Tumor and Advanced Lymphoma, sponsored by CStone Pharmaceuticals.
NCT05279300 is a Phase 1 study of Advanced Solid Tumor and Advanced Lymphoma that is actively recruiting participants, run by CStone Pharmaceuticals. The registered enrollment target is 480 participants, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (153% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05279300, a Phase 1 study of Advanced Solid Tumor and Advanced Lymphoma, is actively recruiting participants, sponsored by CStone Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Lenalidomide
- DRUG Gemcitabine
- BIOLOGICAL Rituximab
- DRUG CS5001
Study Locations (20)
South Australia
- Ashford Cancer Centre Research - Adelaide
- Central Adelaide Local Health Network Incorporated - Adelaide
- Royal Adelaide Hospital (RAH) - Adelaide
Beijing Municipality
- Beijing Cancer Hospital - Beijing
- Beijing Cancer Hospital - Beijing
- Yanda Lu Dao Pei Hospital - Beijing
New York
- North Shore Hematology Oncology Associates - East Setauket
- Columbia U. - Herbert Irving Comprehensive Cancer Center - New York
Victoria
- Epworth Freemasons Medical Centre - East Melbourne
- Epworth Foundation trading as Epworth HealthCare - Melbourne
Anhui
- Anhui Provincial Cancer Hospital - Hefei
- Anhui Provincial Hospital, - Hefei
Guangdong
- Guangdong Province Hospital - Guangzhou
- Sun YatSen University Cancer Center - Guangzhou
Texas
- BUMC - Mary Crowley Cancer Research Centers (MCCRC) - Dallas
New South Wales
- Scientia Clinical Research Limited - Randwick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT05279300 shows while recruiting
NCT05279300 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (153% higher).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT05279300 names 20 study sites across 12 states, led by South Australia, Beijing Municipality, New York.
Frequently Asked Questions
What is clinical trial NCT05279300 about?
NCT05279300 is a clinical study titled "A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas". This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.
What is the current status of trial NCT05279300?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 480 participants. The study started on 2022-03-28. Estimated completion is 2027-12-31.
What conditions does trial NCT05279300 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Advanced Lymphoma.
What interventions are being tested in trial NCT05279300?
The interventions under investigation include: Oxaliplatin (DRUG), Lenalidomide (DRUG), Gemcitabine (DRUG), Rituximab (BIOLOGICAL), CS5001 (DRUG).
Who is sponsoring clinical trial NCT05279300?
This trial is sponsored by CStone Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05279300 being conducted?
This trial has 20 study locations across New York, Texas, New South Wales, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05279300's enrollment target sits among peer trials
480 11th of 189 higher than 179 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI